Novo Nordisk Class Action Lawsuit Filed, Lead Plaintiff Deadline Sept 30

Rosen Law Firm has filed a class action lawsuit on behalf of Novo Nordisk A/S (NYSE: NVO) securities purchasers between May 7, 2025 and July 28, 2025. Investors who purchased securities during this period may be entitled to compensation through a contingency fee arrangement. To join the lawsuit, visit rosenlegal.com or call Phillip Kim, Esq. at 866-767-3653. The deadline to serve as lead plaintiff is September 30, 2025.

Rosen Law Firm has recently filed a class action lawsuit on behalf of Novo Nordisk A/S (NYSE: NVO) securities purchasers between May 7, 2025, and July 28, 2025. Investors who purchased securities during this period may be eligible for compensation through a contingency fee arrangement. To join the lawsuit, visit rosenlegal.com or call Phillip Kim, Esq., at 866-767-3653. The deadline to serve as lead plaintiff is September 30, 2025 [1].

The lawsuit alleges that Novo Nordisk A/S provided misleading statements to investors regarding the company's growth potential. Specifically, the complaint claims that Novo Nordisk overstated its ability to capitalize on the compounded market and understated the impact of the personalization exception to the compounded GLP-1 exclusion. Furthermore, the lawsuit asserts that Novo Nordisk significantly overstated both the size of the GLP-1 market and its ability to penetrate that market to sustain growth [2].

On July 29, 2025, Novo Nordisk announced it was lowering its sales and profit outlook ahead of reporting its results for the second quarter of fiscal year 2025. The company attributed the guidance down on "lowered growth expectations for the second half of 2025" for both Wegovy and Ozempic due to "the persistent use of compounded GLP-1s, slower-than-expected market expectations, and competition." This announcement led to a significant drop in Novo Nordisk's stock price, declining from $69.00 per share on July 28, 2025, to $53.94 per share on July 29, 2025 [3].

Investors should carefully consider the potential impact of the class action lawsuit and the recent guidance adjustments on Novo Nordisk's stock price and financial performance. The company's ability to navigate these challenges will be crucial for its future growth prospects.

References:
[1] https://www.morningstar.com/news/globe-newswire/9508520/rosen-a-ranked-and-leading-law-firm-encourages-novo-nordisk-as-investors-to-secure-counsel-before-important-deadline-in-securities-class-action-nvo
[2] https://robbinsllp.com/novo-nordisk-a-s-class-action/
[3] https://www.ainvest.com/news/novo-nordisk-investors-file-securities-fraud-class-action-lawsuit-2508/